*Statistically significant reduction in liver fat was demonstrated by
Magnetic Resonance Spectroscopy (MRS) in patients completing 52 weeks of
treatment with Aramchol 400mg vs. placebo. Post hoc analysis of MRS
responders, defined by a reduction of ≥5% absolute change from baseline,
demonstrated a clinically and statistically significant effect of Aramchol
600mg vs. placebo.
* Significantly more patients treated with Aramchol 600mg vs. placebo showed
NASH resolution without worsening of fibrosis in the 52-week biopsy, a
regulatory approvable endpoint.
* A higher proportion of patients with at least one-point improvement in
fibrosis score without worsening of NASH was demonstrated in Aramchol
600mg vs. placebo, in the 52-week biopsy, a regulatory approvable
endpoint.
* Statistically significant reductions in ALT and AST were demonstrated in
Aramchol 400mg and 600mg vs. placebo.
* Aramchol continues to show favorable safety and tolerability profile.
Magnetic Resonance Spectroscopy (MRS) in patients completing 52 weeks of
treatment with Aramchol 400mg vs. placebo. Post hoc analysis of MRS
responders, defined by a reduction of ≥5% absolute change from baseline,
demonstrated a clinically and statistically significant effect of Aramchol
600mg vs. placebo.
* Significantly more patients treated with Aramchol 600mg vs. placebo showed
NASH resolution without worsening of fibrosis in the 52-week biopsy, a
regulatory approvable endpoint.
* A higher proportion of patients with at least one-point improvement in
fibrosis score without worsening of NASH was demonstrated in Aramchol
600mg vs. placebo, in the 52-week biopsy, a regulatory approvable
endpoint.
* Statistically significant reductions in ALT and AST were demonstrated in
Aramchol 400mg and 600mg vs. placebo.
* Aramchol continues to show favorable safety and tolerability profile.
